Sartorius Stedim Biotech Acquires Majority Stake in U.S. Start-Up AllPure Technologies

Takeover extends Sartorius Stedim Biotech portfolio for single-use bioprocessing

Sartorius Stedim Biotech (SSB), a leading international supplier for the pharmaceutical and biotech industries, recently announced that it has signed a contract to acquire the majority stake in the U.S. start-up AllPure Technologies LLC.

The privately owned company based in New Oxford, Pennsylvania, USA, has been operating on the market for four years, and in 2013 earned revenue of around U.S. $3 million with 25 employees. AllPure specializes in innovative single-use components for biopharmaceutical applications, such as
aseptic sampling techniques. The parties agreed not to disclose any further details of the purchase agreement.

Reinhard Vogt, member of SSB’s Executive Board commented: “AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently. I am really looking forward to working with the AllPure team and to all thatwe can accomplish together.”

“We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products,” said Michael Zumbrum, President of AllPure.